Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Christoforos G. Kokotos

Christoforos G. Kokotos

University of Athens, Greece

Title: Synthetic methods to 2-hydroxy fatty acids and lipolytic enzyme inhibitors

Biography

Biography: Christoforos G. Kokotos

Abstract

2-Hydroxy fatty acids are important components of a subset of mammalian sphingolipids. Current evidence clearly shows that 2-hydroxy ceramides and 2-hydroxy complex sphingolipids have unique functions in membrane homeostasis and cell signaling. The biosynthesis of 2-hydroxy fatty acids is accomplished by the enzyme fatty acid 2-hydroxylase (FA2H), which stereospecifically produces the (R)-enantiomers. On the other hand, 2-hydroxy oleic acid has been identified as a potent antitumor compound (Minerval) acting against cancer by inducing cell cycle arrest, followed by apoptosis in human leukemia cells or differentiation and autophagy in the case of human glioma cells. In 2011, the European Medicines Agency designated 2-hydroxy oleic acid as an orphan medicinal product for the treatment of glioma. We have been previously involved in the asymmetric organocatalytic α-functionalization of carbonyl compounds. In this presentation, we will discuss our most recent application of these methodologies, as well as the development of novel synthetic approaches for the synthesis of enantioenriched α-substituted fatty acids. We will present the successful application of this methodology in the α-functionalization of fatty acids with hydroxyl, fluoro and sulfenyl moieties. Having in hand a methodology for the fast assembly of chiral and racemic α-functionalized fatty acids, their properties as enzyme inhibitors and signaling-molecules will be pursued. In addition, organocatalytic methodologies for the synthesis of phospholipase A2 inhibitors will be presented.